Top

BMC Cancer

Published in:

Open Access 01-12-2015 | Case report

Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report

Authors: Aline Hempen, Eleftherios P Samartzis, Jivko Kamarachev, Daniel Fink, Konstantin J Dedes

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

Acrokeratosis paraneoplastica is a rare paraneoplastic phenomenon associated with upper aerodigestive tract carcinomas, usually manifesting as psoriasiform keratosis over the acral sites. It is primarily seen in white males above the age of 40 years. Here we report a case of paraneoplastic acrokeratosis in a woman with serous ovarian cancer. To the best of our knowledge, no similar case has been reported previously.

Case presentation

We report the case of a 60-year-old woman diagnosed with a serous ovarian cancer and complaining of a thickening and peeling of the skin on her feet. Clinical and histological examination, as well as the course of disease, confirmed the diagnosis of a paraneoplastic plantar keratosis. Under systemic chemotherapy with carboplatin and paclitaxel the lesion resolved gradually in concordance with tumour marker CA 125.

Conclusions

We present the reported case of paraneoplastic acrokeratosis associated with advanced high-grade ovarian cancer.

Bazex A, Salvador R, Dupre A, Christol B. Syndrome paranéoplasieque à type d’hyperkératose des extrémités. Guérison après le traitement de l’épit-hélioma laryng. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.

Bolognia J. Bazex syndrome: acrokeratosis paraneoplastica. Sem in Dermatol. 1995;14:84–9.CrossRef

Valdivielso M, Longo I, Suàrez R, Huerta M, Làzaro P. Acrokeratosis paraneoplastica: bazex syndrome. J Eur Acad Dermatol Venerol. 2005;19:340–4.CrossRef

Karabulut A, Sahin S, Sahin M, Eksioglu M, Ustün H. Paraneoplastic acrokeratosis of Bazex (Bazex’s syndrome): report of a female case associated with cholangiocarcinoma and review of the published work. J Dermatol. 2006;33:850–4.CrossRefPubMed

Abrou A, Hope J, Jackson-Richards D, Lim H, Ozog D. Acrodermatitis paraneoplastica responding to topical PUVA treatment. Photodermatol Photoimmunol Photomed. 2007;23:37–8.CrossRefPubMed

Poligone B, Christensen SR, Lazova R, Heald PW. Bazex syndrome (acrokeratosis paraneoplastica). Lancet. 2007;369:530.CrossRefPubMed

Fasanmade A, Farrell K, Perkins CS. Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm. Br J Oral Maxillofac Surg. 2009;47:138–9.CrossRefPubMed

Abreu Velez A, Howard M. Diagnosis and treatment of cutaneous paraneoplastic disorders. Dermatol Ther. 2010;23:662–75.CrossRefPubMed

Taher M, Grewal P, Gunn B, Tonkin K, Lauzon G. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg. 2007;11:78–83.CrossRefPubMed

10.

Hara M, Hunayama M, Aiba S, Suetake T, Watanabe M, Tanaka M, et al. Acrokeratosis paraneoplastica (Bazex syndrome) associated with primary cutaneous squamous cell carcinoma of the lower leg, vitiligo and alopecia areata. Br J Dermatol. 1995;133(1):121–4.CrossRefPubMed

11.

Bolognia J, Brewer Y, Cooper D. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore). 1991;70:269–80.CrossRef

12.

Hudson C, Curling M, Potsides P, Lowe D. Paraneoplastic synromes in patients with ovarian neoplasia. J Royal Soc Med. 1993;86:202–4.

13.

Da Silva JA, De Carvalho Mesquita K, De Souza Machado Igreja A, Rodrigues Naves Lucas I, Ferreira Freitas A, de Maximiano Oliveira S, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013;88(1):9–22.CrossRefPubMedPubMedCentral

14.

Fader A, Winder A, Sandadi S, DeBernardo R. Sweet’s syndrome: a cutaneous harbinger of ovarian carcinoma. Case report. J Gynecol Oncol. 2012;4:288–90.CrossRef

Title: Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report
Authors: Aline Hempen
Eleftherios P Samartzis
Jivko Kamarachev
Daniel Fink
Konstantin J Dedes
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1527-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Laparoscopy versus laparotomy for the management of early stage cervical cancer

SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer

Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies

A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial)

Randomized phase II study of S-1 dosing schedule for resected colorectal cancer

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer